Critical Contrast: Vertex Pharmaceuticals (NASDAQ:VRTX) & Werewolf Therapeutics (NASDAQ:HOWL)

Werewolf Therapeutics (NASDAQ:HOWL) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Werewolf Therapeutics and Vertex Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1	4	2	0	2.14
Vertex Pharmaceuticals	0	2	25	1	2.96

Werewolf Therapeutics presently has a consensus target price of $4.00, suggesting a potential upside of 311.52%. Vertex Pharmaceuticals has a consensus target price of $596.44, suggesting a potential upside of 8.81%. Given Werewolf Therapeutics’ higher probable upside, equities analysts clearly believe Werewolf Therapeutics is more favorable than Vertex Pharmaceuticals.

Valuation & Earnings

This table compares Werewolf Therapeutics and Vertex Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88 million	25.13	-$60.82 million	($0.76)	-1.28
Vertex Pharmaceuticals	$12.00 billion	11.58	$3.95 billion	$15.54	35.27

Vertex Pharmaceuticals has higher revenue and earnings than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Werewolf Therapeutics has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500.

Profitability

This table compares Werewolf Therapeutics and Vertex Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-166.99%	-59.88%
Vertex Pharmaceuticals	30.70%	21.98%	15.50%

Summary

Vertex Pharmaceuticals beats Werewolf Therapeutics on 11 of the 15 factors compared between the two stocks.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.